| Detected | Trial | Change |
|---|---|---|
| 2026-08-04 | NCT04176198 A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis |
Trial sites expanded: 84 -> 90 locations |
| 2026-07-30 | NCT05023551 Study of DSP-0390 in Patients With Recurrent High-Grade Glioma |
date change Primary completion pushed: 2026-09-30 -> 2027-09-30 |
| 2026-07-30 | NCT05023551 Study of DSP-0390 in Patients With Recurrent High-Grade Glioma |
date change Completion pushed: 2026-10-31 -> 2027-10-31 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 1/2 | |||
| NCT06753331 | A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083… | Parkinson's Disease | Recruiting |
| NCT04988555 | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | Leukemia, Myeloid, Acute | Recruiting |
| NCT06891885 | A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male… | Retinitis Pigmentosa | Recruiting |
| NCT04176198 | A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis | Myelofibrosis | Recruiting |
| NCT06526819 | SMP-3124LP in Adults With Advanced Solid Tumors | Solid Tumor | Recruiting |
| Phase 1 | |||
| NCT07444268 | How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single… | Advanced Hematologic Malignancies | Recruiting |
| Early Phase 1 | |||
| NCT05023551 | Study of DSP-0390 in Patients With Recurrent High-Grade Glioma | High Grade Glioma | Active, Not Recruiting |
| Not specified | |||
| NCT06517940 | A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP) | Retinitis Pigmentosa | Active, Not Recruiting |